SRI Biosciences advances patient-derived tumor xenograft (PDX) models to the cellular level, effectively recapitulating human tumors. SRI’s PDCellX™ models provide clinically relevant information that allows researchers to evaluate the efficacy of cancer drug candidates in new models that recapitulate the heterogeneity of tumors and go beyond traditional tumor xenograft endpoints.

Our PDCellX technology uses dissociated tumor cells from surgical biopsies that can be reconstructed through implants in mice to reflect the complexity and diversity of tumor cell subpopulations. By implanting dissociated cells, tumor heterogeneity is equally distributed—and the engraftment and tumor growth are more efficient, compared to tumor fragments. PDCellX models succeed in retaining primary tumor properties and metastatic behavior.

Current PDCellX models include human breast, colon, lung, and pancreas. Additional models are in development.

SRI’s expert cancer pharmacologists working with PDCellX provide:

**Customized efficacy studies**
- Designed to meet your project objectives

**Shorter time to results than standard PDX**
- PDCellX can reduce study time in half

**Refined testing in a clinically relevant model**
- PDCellX captures the heterogeneity of the primary tumor and reduces data variability

**Early identification of biomarkers**
- Strengthens their predictive nature

**Opportunity to study tumor diversity and molecular characteristics at the cellular level**
- Tumor drug resistance
- Likelihood of drug-treated cells to reinitiate tumors
- Migration
- Pro-angiogenic activity
- Metastatic properties

**Increased opportunity for success in the clinic**
- Closest available alternative to clinical testing
Proven Range of Discovery Expertise

Our highly experienced preclinical team evaluates anticancer agents to expedite drug development for industry, government, and academic partners. SRI Biosciences’ Center for Cancer and Metabolism discovers and develops novel approaches to cancer treatment by integrating basic research with industry-honed disciplines.

SRI’s expertise includes high-throughput screening (HTS) and high-content screening (HCS), as well as the design and performance of in vitro assays and in vivo efficacy studies. We also offer imaging endpoints, and detection and analysis of circulating tumor cells in blood and bone marrow.

Support services also include molecular biology, biochemistry, imaging, histopathology, and onsite irradiator capabilities.

Additional Cancer Efficacy Services

In addition to PDCellX tumor modeling services, SRI Biosciences also offers these model types:

- Human tumor cell line-derived murine xenograft models—orthotopic and subcutaneous

- More than 18 human tumor tissue types and 80 cell lines, including breast, cervical, colon, leukemia, liver, lung, ovarian, pancreatic, and prostate. Additional tumor-forming lines are available upon request.

- Syngeneic mouse models, including colon carcinoma, melanoma, and pancreatic carcinoma

- Angiogenesis with in vivo human skin graft model

From Idea to IND and Beyond™

SRI Biosciences is a well-established, trusted source for a wide array of contract services under the highest industry standards. With deep scientific resources and expertise, we take R&D from idea to discovery through the start of human clinical trials. SRI Biosciences specializes in cancer, immunology and inflammation, infectious disease, and neuroscience.

Contact Us

Let’s discuss how SRI Biosciences can help you achieve your research goals.

Email: biosciences@sri.com
Phone: +1.650.859.3000
Toll-Free: +1.866.451.5998

www.sri.com/biosciences